Back to List View Graph View

Docetaxel

Docetaxel is a chemotherapeutic agent belonging to the taxane family, primarily used in the treatment of various malignancies, including breast, lung, and prostate cancers.

Where the papers sit

15 papers from the last 6 months study docetaxel directly · updated from PubMed 16 Nov 2026

  • Prostate Cancer Treatment

    Docetaxel is being positioned within intensified and biomarker-guided treatment for advanced prostate cancer. Real-world data compare it with androgen receptor pathway inhibitors and evaluate darolutamide triplets in metastatic hormone-sensitive disease. PRR7, Wnt/β-catenin signaling, and testosterone-treatment effects point toward molecular selection, while neutropenia and fatigue remain practical limits. Micellar docetaxel formulations and predictive models broaden the search for safer, more effective therapy.

    6 papers · 40%

  • Targeted Docetaxel Delivery

    Docetaxel delivery is shifting toward targeted systems designed to improve tumor exposure and limit systemic loss. Folate-targeted polymeric micelles, iRGD peptide conjugates, and PLA–gelatin nanofibers aim to increase uptake or brain penetration in glioblastoma. aCD47 conjugation adds immune activation to chemotherapy against immunologically cold tumors. Evidence remains mainly pharmacokinetic, in vitro, or early preclinical, with clinical feasibility extending to divided-dose DCF in esophageal cancer.

    5 papers · 33.3%

  • Docetaxel Toxicity and Response

    Docetaxel research in breast cancer is balancing antitumor efficacy against treatment-related toxicity. Cuproptosis induction through lncRNA AC008406.3 is presented as a route to resensitize resistant cells, while desloratadine is evaluated for preventing skin toxicity. Peripheral edema is being quantified as a cross-tumor safety problem, and eribulin is compared with docetaxel in HER2-directed first-line regimens. The emphasis is on better selection and supportive care rather than docetaxel alone.

    4 papers · 26.7%

NEW DIRECTION

In syngeneic cold glioblastoma, docetaxel functions as an immune-priming component of localized immuno-chemotherapy

The aCD47-docetaxel immuno-chemotherapy study in syngeneic “cold” glioblastoma models treats docetaxel not only as a cytotoxic drug but as the first step in a two-stage immune response: it kills tumor cells and exposes tumor antigens, after which anti-CD47 enables macrophage-mediated clearance and promotes T-cell recruitment. This assigns docetaxel an immune-priming role outside the cytotoxic, delivery, toxicity-management, and resistance-related roles used by the other papers, with combined local delivery through μMESH more than doubling median survival and producing long-term survival in 40% of mice 42486280Jul.

docetaxel chemical structure

Papers

The 15 papers from the last 6 months that study docetaxel directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Prostate Cancer Treatment (6)
  1. Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial. Cancer chemotherapy and pharmacology · 29 Aug 2026 PMID 42667368
  2. A Combined Chemoinformatics- and Machine Learning-Based Approach Identifies Chlormidazole as a Drug Repurposing Candidate against Aggressive Prostate Cancer. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593938
  3. Integrated transcriptomic and functional analyses identify PRR7 as a therapeutic target that associated with Wnt/β-catenin signaling and docetaxel resistance in prostate cancer. Biochemical and biophysical research communications · 1 Aug 2026 PMID 42542043
  4. Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study. Japanese journal of clinical oncology · 9 Jul 2026 PMID 42424546
  5. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer. Current medical research and opinion · 8 Jun 2026 PMID 42258330
  6. Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis. Cancer · 23 May 2026 PMID 42175549
Targeted Docetaxel Delivery (5)
  1. Electrospun PLA: Gelatin core-shell nanofibers for dual delivery of docetaxel and heparin with enhanced in vitro antiproliferative activity. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 7 Aug 2026 PMID 42567422
  2. Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
  3. aCD47-docetaxel immuno-chemotherapy: A two-pronged attack against 'cold' glioblastoma. Journal of controlled release : official journal of the Controlled Release Society · 22 Jul 2026 PMID 42486280
  4. iRGD-modified peptide-drug conjugate improves brain delivery and antitumor efficacy in glioblastoma. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2 Jul 2026 PMID 42392327
  5. In Vivo Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles. Cancer investigation · 21 Jun 2026 PMID 42324122
Docetaxel Toxicity and Response (4)
  1. Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 19 Oct 2026 PMID 42895563
  2. Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study. Japanese journal of clinical oncology · 26 Jul 2026 PMID 42502974
  3. Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. Breast cancer research and treatment · 8 Jul 2026 PMID 42420599
  4. Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. Cancer biology & therapy · 26 May 2026 PMID 42189063

By study type

Clinical trials (3)
  1. Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial. Cancer chemotherapy and pharmacology · 29 Aug 2026 PMID 42667368
  2. Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. Breast cancer research and treatment · 8 Jul 2026 PMID 42420599
  3. Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis. Cancer · 23 May 2026 PMID 42175549
Observational studies and case reports (3)
  1. Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 19 Oct 2026 PMID 42895563
  2. Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
  3. Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study. Japanese journal of clinical oncology · 26 Jul 2026 PMID 42502974
Preclinical: animal, cell and lab studies (7)
  1. A Combined Chemoinformatics- and Machine Learning-Based Approach Identifies Chlormidazole as a Drug Repurposing Candidate against Aggressive Prostate Cancer. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593938
  2. Electrospun PLA: Gelatin core-shell nanofibers for dual delivery of docetaxel and heparin with enhanced in vitro antiproliferative activity. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 7 Aug 2026 PMID 42567422
  3. Integrated transcriptomic and functional analyses identify PRR7 as a therapeutic target that associated with Wnt/β-catenin signaling and docetaxel resistance in prostate cancer. Biochemical and biophysical research communications · 1 Aug 2026 PMID 42542043
  4. aCD47-docetaxel immuno-chemotherapy: A two-pronged attack against 'cold' glioblastoma. Journal of controlled release : official journal of the Controlled Release Society · 22 Jul 2026 PMID 42486280
  5. iRGD-modified peptide-drug conjugate improves brain delivery and antitumor efficacy in glioblastoma. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2 Jul 2026 PMID 42392327
  6. In Vivo Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles. Cancer investigation · 21 Jun 2026 PMID 42324122
  7. Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. Cancer biology & therapy · 26 May 2026 PMID 42189063
Unclassified: not yet indexed with MeSH (2)
  1. Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study. Japanese journal of clinical oncology · 9 Jul 2026 PMID 42424546
  2. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer. Current medical research and opinion · 8 Jun 2026 PMID 42258330